← Back to Search

Monoclonal Antibodies

STRO-002 + Bevacizumab for Ovarian Cancer

Phase 1
Waitlist Available
Research Sponsored by Sutro Biopharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline through end of study (approximately 24 months)
Awards & highlights

Summary

This trial is testing a new drug to see if it is safe and effective when used with another drug to treat cancer.

Who is the study for?
This trial is for adults over 18 with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. They should have a life expectancy of more than 3 months and at least one measurable lesion. Participants need good kidney, bone marrow, and liver function but can't join if they've had certain treatments like FolRα targeting agents or are pregnant/breastfeeding without using barrier contraception.Check my eligibility
What is being tested?
The study tests STRO-002 combined with Bevacizumab in patients with epithelial ovarian cancer to evaluate safety and early effectiveness. It's a Phase 1 trial where participants' response to the treatment is monitored through various health parameters.See study design
What are the potential side effects?
While specific side effects aren't listed here, typical reactions may include issues related to antibody-drug conjugates such as allergic reactions, lowered blood cell counts leading to increased infection risk or bleeding problems, fatigue, nausea, and potential organ damage.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline through end of study (approximately 24 months)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline through end of study (approximately 24 months) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part 1 - Determine the recommended phase 2 dose (RP2D) of STRO-002/bevacizumab
Part 1 - Safety and tolerability of STRO-002/bevacizumab as a combination therapy
Secondary outcome measures
Part 1 - Assess the formation of anti-drug antibodies (ADAs) to STRO-002 when administered with bevacizumab.
Part 1 - Characterize the PK of STRO-002 by measuring the area under the plasma concentration versus time curve (AUC)
Part 1 - Characterize the pharmacokinetics (PK) of STRO-002 by measuring the maximum plasma concentration (Cmax).

Side effects data

From 2015 Phase 4 trial • 45 Patients • NCT02036424
22%
vitreous hemorrhage
17%
worsening of cataract
9%
posterior capsule opacification
9%
vitreous syneresis
4%
cranial nerve VI palsy
4%
bradycardia
4%
pneumonia
4%
pyelonephritis
4%
colon cancer
100%
80%
60%
40%
20%
0%
Study treatment Arm
Bevacizumab
Ozurdex

Trial Design

1Treatment groups
Experimental Treatment
Group I: Experimental :STRO-002 treatment in combination with BevacizumabExperimental Treatment2 Interventions
Dose Escalation: STRO-002 at increasing dose levels plus bevacizumab at 15 mg/kg Dose Expansion: STRO-002 at RP2D plus bevacizumab at 15 mg/kg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
2013
Completed Phase 4
~5280

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
STRO-002 is an antibody-drug conjugate that targets folate receptor alpha, delivering cytotoxic agents directly to ovarian cancer cells, thereby minimizing damage to healthy cells. Bevacizumab, on the other hand, is a monoclonal antibody that inhibits VEGF, preventing the formation of new blood vessels that tumors need for growth and metastasis. These targeted therapies are significant for ovarian cancer patients as they offer the potential for improved efficacy and reduced side effects compared to traditional chemotherapy.

Find a Location

Who is running the clinical trial?

Sutro Biopharma, Inc.Lead Sponsor
4 Previous Clinical Trials
962 Total Patients Enrolled
2 Trials studying Ovarian Cancer
760 Patients Enrolled for Ovarian Cancer
Arturo Molina, MDStudy ChairSutro Biopharma
2 Previous Clinical Trials
230 Total Patients Enrolled
1 Trials studying Ovarian Cancer
160 Patients Enrolled for Ovarian Cancer

Media Library

Bevacizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05200364 — Phase 1
Ovarian Cancer Research Study Groups: Experimental :STRO-002 treatment in combination with Bevacizumab
Ovarian Cancer Clinical Trial 2023: Bevacizumab Highlights & Side Effects. Trial Name: NCT05200364 — Phase 1
Bevacizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05200364 — Phase 1
~21 spots leftby Dec 2025